ホーム>>Signaling Pathways>> Microbiology & Virology>> HBV>>Helioxanthin 8-1

Helioxanthin 8-1

カタログ番号GC13722

ヘリオキサンチン 8-1 はヘリオキサンチンの類似体であり、>5/10/1.4/15 uM の EC50 で有意な in vitro 抗 HBV/HCV/HSV-1/HIV 活性を示します。

Products are for research use only. Not for human use. We do not sell to patients.

Helioxanthin 8-1 化学構造

Cas No.: 840529-13-7

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$261.00
在庫あり
2mg
$210.00
在庫あり
5mg
$315.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Helioxanthin 8-1, an analogue of helioxanthin (ACH126447), is an inhibitor of HBV and HIV virus with EC50 values of 0.03 μM and 2.7 μM, respectively [1].

Helioxanthin 8-1 is the cyclic hydrazide derivative of helioxanthin and has shown significant in vitro antivirus activity with EC50 values of 0.03 μM and 2.7 μM for HBV and HIV, respectively [1]. In the ds-tet5 cells, helioxanthin 8-1 can inhibit duck hepatitis B virus (DHBV) DNA synthesis with a mean IC50 value of 0.25±0.05 μM. Besides, in induced cells and non-induced ds-tet5 cells, helioxanthin 8-1 has cytotoxic effect with CC50 values of 18±2 μM and 45±3 μM, respectively, by using an MTT assay [2].

References:
[1] Yeo H1, Li Y, Fu L, Zhu JL, Gullen EA, Dutschman GE, Lee Y, Chung R, Huang ES, Austin DJ, Cheng YC. Synthesis and antiviral activity of helioxanthin analogues. J Med Chem. 2005 Jan 27;48(2):534-46.
[2] Ying C1, Tan S, Cheng YC.  Helioxanthin analogue 8-1 inhibits duck hepatitis B virus replication in cell culture. Antivir Chem Chemother. 2010;21(2):97-103.

レビュー

Review for Helioxanthin 8-1

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Helioxanthin 8-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.